TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01574378

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional closure
Description: non barbed sutures used to close wounds Conventional three layer wound closure using non-locking sutures polyglactin 910 (Vicryl, Ethicon) and polyglecaprone 25 (Monocryl, Ethicon)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Loc 90
Description: 2-layer wound closure using V-Loc 90 barbed suture
Study: NCT01763801

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P-Max
Description: tip placement in correspondence to the P-Max on the ECG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P-Submax
Description: tip placement in correspondence to the P-Submax on the ECG
Study: NCT04315259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: irrigation activated by diode laser versus soft tissue laser application therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: irrigation activated by diode laser versus soft tissue laser application therapy
Study: NCT02884895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Tube Suction
Description: Intubating Laryngeal Tube Suction Disposable

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: Direct Laryngoscopy
Study: NCT02424734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline Fosamil
Description: Ceftaroline fosamil will be given at a dose of 6 mg/kg IV over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin
Description: Ampicillin IV is required for the first 48 hours if the presence of an organism that requires treatment with ampicillin cannot be excluded. Will be given as per local standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoglycoside
Description: Optional, will be given as per local standard of care.
Study: NCT03387670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: * One (1 = 40mg) simvastatin tablet once daily at night for 1 month~* Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 to 53 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * One (1) placebo tablet once daily at night for 1 month~* Two (2) placebo tablets once daily at night, for the next 35 to 53 months
Study: NCT00948064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
Study: NCT00379015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study: NCT01043575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: During the first 8 weeks of therapy for TB participants \> 45 kg will receive rifapentine 600 mg orally given 5 per week and for participants \< 45 kg participants will receive 450 mg orally given 5 days per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: During the first 8 weeks of therapy participants will receive rifampin at standard doses (e.g. 600 mg) 5 days per week
Study: NCT03432325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Enabled Prosthesis
Description: Surgically implanted neural enabled prosthesis
Study: NCT03991780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
Study: NCT03840317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19-targeting CAR T cells
Description: Autologous CD19-targeting CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19-targeting CAR T cells
Description: Autologous CD19-targeting CAR T cells
Study: NCT00782535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 4226 pMDI
Description: Inhaled solution, single therapeutic dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 4226 pMDI
Description: Inhaled solution, single therapeutic dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 4226 pMDI
Description: Inhaled solution, single supratherapeutic dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 4226 pMDI
Description: Inhaled solution, single supratherapeutic dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled solution, single dose of placebo
Study: NCT02031575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Treatment
Description: Mobile phone text messaging service about reproductive health

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Treatment
Description: Mobile phone text messaging service about reproductive health

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control, comparator arm
Study: NCT02558959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT01414634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETIMS
Description: injection of peptide-coupled PBMC by i.v. infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETIMS
Description: injection of peptide-coupled PBMC by i.v. infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETIMS
Description: injection of peptide-coupled PBMC by i.v. infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETIMS
Description: injection of peptide-coupled PBMC by i.v. infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETIMS
Description: injection of peptide-coupled PBMC by i.v. infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETIMS
Description: injection of peptide-coupled PBMC by i.v. infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETIMS
Description: injection of peptide-coupled PBMC by i.v. infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETIMS
Description: injection of peptide-coupled PBMC by i.v. infusion
Study: NCT05354661

Intervention type: DEVICE
Intervention: Hypotension Prediction Index
Description: treatment of hypotension before the appearance following HPI algorithm
Study: NCT03046186

Intervention type: DIAGNOSTIC_TEST
Intervention: Mixed meal test with double tracer technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Mixed meal test with double tracer technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Mixed meal test with double tracer technique
Study: NCT00232765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER Sirolimus-Eluting Stent
Description: CYPHER Sirolimus-Eluting Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncoated BX VELOCITY Balloon-Expandable Stent
Description: Uncoated BX VELOCITY Balloon-Expandable Stent
Study: NCT03043014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifépristone versus Misoprostol
Description: The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifépristone versus Misoprostol
Description: The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
Study: NCT00848809

Intervention type: PROCEDURE
Intervention: Blood sample
Description: 9 blood samples will be sent to the laboratory for the subjects in the SLED cohort

Intervention type: PROCEDURE
Intervention: Blood sample
Description: 10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
Study: NCT03985930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distraction with virtual reality
Description: Distraction content delivered through virtual reality goggles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual
Study: NCT02632799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHF small cannula
Description: NHF 8 l/min by Airvo 2 by small cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHF big cannula
Description: NHF 8 l/min by Airvo 2 by large cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Nsal CPAP 5cm H2o by face mask
Study: NCT03877276

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: a prepared meal consisting of pastry and 2 cooked egg whites

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: a prepared meal consisting of pastry and 2 cooked egg whites

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: a prepared meal consisting of pastry and 2 cooked egg whites

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: a prepared meal consisting of pastry and 2 cooked egg whites

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: a prepared meal consisting of pastry and 2 cooked egg whites

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: a prepared meal consisting of pastry and 2 cooked egg whites

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: a prepared meal consisting of pastry and 2 cooked egg whites

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: a prepared meal consisting of pastry and 2 cooked egg whites

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spinach smoothie
Description: a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spinach smoothie
Description: a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spinach smoothie
Description: a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kale smoothie
Description: prepared blended kale smoothie, consisting of banana, avocado, orange juice, and kale

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blended smoothie
Description: a prepared blended smoothie, consisting of banana, avocado, and orange juice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: V spinach smoothie
Description: a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and a varying amount (low, medium, high) of spinach

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium oxalate drink
Description: a prepared sodium oxalate drink
Study: NCT02061787

Intervention type: DEVICE
Intervention: balloon pulmonary angioplasty
Description: patients with chronic thromboembolic pulmonary hypertension who underwent balloon pulmonary angioplasty
Study: NCT00490087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (IUD)
Study: NCT04142203

Intervention type: OTHER
Intervention: 23 h surgery
Description: Patients were treated in 23 surgical unit
Study: NCT01584232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylureas (SU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylureas (SU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biguanide (BG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biguanide (BG)
Study: NCT02125396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization
Description: Adjuvant transarterial chemoembolization \[5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Description: Adjuvant transarterial chemoembolization \[5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Adjuvant radiotherapy is used for postoperative curative HCC
Study: NCT00116753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10
Study: NCT02125396

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Adjuvant radiotherapy is used for postoperative curative HCC
Study: NCT03795571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2，d0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2，d1，d5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 75mg/m2，d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg/d，d1\~d4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide Oral Capsule
Description: Lenalidomide 10mg/d、15mg/d、20mg/d、25mg/d d1\~d10； 21days a cycle
Study: NCT02627170

Intervention type: DEVICE
Intervention: dynamic Scheimpflug analyzer (corneal visualization Scheimpflug technology [Corvis ST], OCULUS, Wetzlar, Germany)
Study: NCT02877329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered ACT
Description: Therapist-guided Internet-delivered ACT (acceptance and commitment therapy) for 8 weeks
Study: NCT04642300

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmich Protocol
Description: Module 1 (1st two weeks):~i)Isometric adduction ii)Abdominal sit-ups iii)Isometric adduction iv)Compound abdominal sit-ups and hip flexion v)Balance exercise on wobble board vi)One-foot exercise on sliding board~Module 2 (from 3rd week):~i)Leg abduction and adduction exercise carried out in side lying ii)Low back extension exercise prone on the end of bench iii)One leg weight pulling abduction/adduction standing iv)Abdominal sit ups v)One leg coordination exercise vi)Training in sideways motion vii)Balance exercise on wobble board

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release Technique
Description: 1. Transverse friction massage: 10 mins on painful area of adductor-tendon insertion into pubic bone~2. Stretching of adductor muscles, hamstrings muscles and hip flexors:3 times and each stretch is 30s with Contract relax technique
Study: NCT01578200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Study: NCT04054700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: distal upper rehabilitation robot
Description: Intervention with distal upper rehabilitation robot

Intervention type: DEVICE
Group type: OTHER
Intervention: proximal upper rehabilitation robot
Description: Intervention with proximal upper rehabilitation robot
Study: NCT00762359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefarnate
Description: Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
Study: NCT02490436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Randomized cross-over between cetuximab and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Randomized cross-over between cetuximab and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized cross-over between cetuximab and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized cross-over between cetuximab and placebo
Study: NCT02198014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: 5 minutes. Thermotherapy shallow to 50 cm away from the knee. 15 minutes. Joint traction, grade I-II. Fixation of distal femur with cinch and manual fixation of proximal tibia. Patient in prone position and the traction is carried out in the submaximal ranges of flexion and extension.~10 minutes. Passive muscle stretching of quadriceps (within the limits of mobility), through compression muscle, passive muscle stretching and relaxation of muscle.~10 minutes. Isometric and resisted exercises of quadriceps, in submaximal ranges, of flexion and extension.~10 minutes. Proprioception exercises with unipodal support, with and without visual support, and posterior destabilization.~10 minutes. Local cryotherapy with ice pack.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Physiotherapy
Description: * Theory. Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of knee; Anatomy of ankle musculature; Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; active exercises for mobility and pain management; knee proprioception exercises; isometric and isotonic exercises of quadriceps; swimming and cycling technique.
Study: NCT00928486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
Study: NCT01048879

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pharmacokinetic blood sampling
Description: blood samples collected to assess oseltamivir concentrations

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pharmacokinetic blood and dialysate sampling
Description: blood and dialysate samples collected and assayed for oseltamivir concentrations

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pharmacokinetic blood and dialysate sampling
Description: blood and dialysate samples collected and assayed for oseltamivir concentrations